New vaccines for a safer world
As the COVID-19 pandemic shows, in a world characterised by increasing population density, human mobility, and ecological change, emerging infectious diseases (EIDs) pose a real and growing threat to global health security.
Epidemic diseases affect us all. They do not respect borders.
The costs of EIDs are vast, in both human and economic terms. As well as the devastating death toll and disruption to societies, COVID-19 could cost the global economy $4.1 trillion, or almost 5% of global gross domestic product. Even small epidemics can cause tremendous economic disruption.
Vaccines are one of our most powerful tools in the fight to outsmart epidemics. The development of vaccines can help save lives, protect societies and restabilise economies.
The Coalition for Epidemic Preparedness Innovations’ (CEPI’s) mission is to stimulate and accelerate the development of vaccines against emerging infectious diseases and enable access to these vaccines for people during outbreaks.
Scientist harvesting flu virus
Historically, vaccine development has been a long, risky, and costly endeavour. Planning for emerging infectious diseases is especially challenging: the market potential for vaccines against these diseases is limited and testing such vaccines is difficult.
We need a better system to speed the development of vaccines against emerging infectious diseases.
Events like the devastating 2014/15 outbreak of Ebola in West Africa—which killed more than 11,000 people and had an economic and social burden of over $53 billion—showed us that very few vaccines are ready to be used against these threats.
The world’s response to this crisis fell tragically short. A vaccine that had been under development for more than a decade was not deployed until over a year into the epidemic. That vaccine was shown to be 100% effective, suggesting that much of the epidemic could have been prevented.
The creation of CEPI
The Coalition for Epidemic Preparedness Innovations (CEPI) was launched at Davos 2017 as the result of a consensus that a coordinated, international, and intergovernmental plan was needed to develop and deploy new vaccines to prevent future epidemics.
We are an innovative global partnership between public, private, philanthropic, and civil society organisations working to accelerate the development of vaccines against emerging infectious diseases and enable equitable access to these vaccines for affected populations during outbreaks.
Close collaboration with global partners are crucial to ensure the success of our work. Therefore, we will support coordinating activities to improve our collective response to epidemics, strengthening capacity in countries at risk, and advancing the regulatory science that governs product development.